Alebund Pharmaceuticals

Shanghai, China · Founded 2018 · In IPO Registration

Operator of a biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions. Alebund Pharmaceuticals is based in Shanghai, China and was founded in 2018. Its last reported valuation was $530 million in Oct 2025. It has raised $270 million.

Last reported valuation
$530.5M
Oct 2026
Priced at
—
Total raised
$269.8M
Last round
—

Who backs Alebund Pharmaceuticals?

25 investors
InvestorType
GIC PrivateOther
5Y CapitalOther
YuanBio Venture CapitalVenture capital
Tencent InvestmentOther
Morningside GroupVenture capital
HT CCVenture capital
Loyal Valley CapitalVenture capital
Ausvic CapitalVenture capital
Octagon Capital AdvisorsHedge fund
QS CapitalOther
+ 15 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Alebund Pharmaceuticals investors

25 investors are on record for Alebund Pharmaceuticals, including GIC Private, 5Y Capital, YuanBio Venture Capital and Tencent Investment. By type, the record holds 5 venture capital firms and 2 hedge funds.

Free account
More of Alebund Pharmaceuticals with a free account
  • ·The complete investor list: 25 names
  • ·Watch Alebund Pharmaceuticals: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 25 firms already write checks for companies like Alebund Pharmaceuticals. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View